Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros

摘要

BackgroundThe development of therapies for sickle cell disease has received special attention, particularly those that reduce the polymerization of hemoglobin S. Hydroxyurea is a commonly used medication because it has the ability to raise levels of fetal hemoglobin, decrease the frequency of vaso-occlusive episodes and thus improve the clinical course of sickle cell disease patients.